LGND (STOCKS)
Ligand Pharmaceuticals Inc.
$288.820000
-4.450000 (-1.52%)
Prev close: $293.270000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Todd Christopher Davis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5,781.65M
- Employees
- 68
- P/E (TTM)
- 31.35
- P/B (TTM)
- 6.04
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $290.54M |
| Benefits Costs and Expenses | $52.58M |
| Costs And Expenses | $52.58M |
| Nonoperating Income/Loss | $143.23M |
| Operating Expenses | $195.81M |
| Research and Development | $41.35M |
| Other Operating Expenses | $154.46M |
| Operating Income/Loss | $94.73M |
| Income/Loss From Continuing Operations After Tax | $197.22M |
| Income/Loss From Continuing Operations Before Tax | $237.96M |
| Income Tax Expense/Benefit | $40.74M |
| Net Income/Loss | $197.22M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $197.22M |
| Net Income/Loss Available To Common Stockholders, Basic | $197.22M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $10.07 |
| Diluted Earnings Per Share | $9.41 |
| Basic Average Shares | 39,523,000 |
| Diluted Average Shares | 62,473,000 |
| Assets | $2.19B |
| Current Assets | $1.46B |
| Inventory | $10.26M |
| Other Current Assets | $1.45B |
| Noncurrent Assets | $728.76M |
| Fixed Assets | $3.40M |
| Intangible Assets | $209.24M |
| Other Non-current Assets | $516.12M |
| Liabilities | $1.22B |
| Current Liabilities | $46.74M |
| Accounts Payable | $9.41M |
| Wages | $4.64M |
| Other Current Liabilities | $32.70M |
| Noncurrent Liabilities | $1.17B |
| Long-term Debt | $1.13B |
| Other Non-current Liabilities | $45.03M |
| Equity | $967.52M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $967.52M |
| Liabilities And Equity | $2.19B |
| Net Cash Flow From Operating Activities | $131.71M |
| Net Cash Flow From Operating Activities, Continuing | $131.71M |
| Net Cash Flow From Investing Activities | -$144.78M |
| Net Cash Flow From Investing Activities, Continuing | -$144.78M |
| Net Cash Flow From Financing Activities | $950.28M |
| Net Cash Flow From Financing Activities, Continuing | $950.28M |
| Exchange Gains/Losses | -$995.00K |
| Net Cash Flow | $936.22M |
| Net Cash Flow, Continuing | $937.21M |
| Comprehensive Income/Loss | $196.27M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $193.20M |
| Other Comprehensive Income/Loss | $209.61M |